Lee's Pharmaceutical Holdings Limited
李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)
(Stock Code: 950)

VOLUNTARY ANNOUNCEMENT

BUSINESS UPDATE ON THE LICENSING AGREEMENT IN RELATION TO THE DEVELOPMENT, MANUFACTURE AND COMMERCIALISATION OF OC-3

This announcement is made by the board (the "**Board**") of directors (the "**Directors**") of Lee's Pharmaceutical Holdings Limited (the "**Company**" or "**Lee's Pharm**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The Board of the Company is pleased to announce that Lee's Pharmaceutical (HK) Limited ("**LPHK**"), a wholly-owned subsidiary of the Group, and 1cBio, Inc. ("**1cBio**"), a US-based biotech company developing precision medicines for significant unmet needs, entered into an exclusive licensing agreement (the "**Agreement**") for the development, manufacture and commercialisation of OC-3, a PARP1 inhibitor for the treatment of cancers that are defective in DNA homologous recombination repair, including prostate, ovarian, breast and pancreatic cancers with known mutations in DNA repair genes such as BRCA1, BRCA2 or PALB2, in Mainland China, Hong Kong, Macau, Taiwan, and certain other countries in Southeast Asia (the "**Territory**").

Pursuant to the Agreement, LPHK will be responsible for the GLP safety studies and manufacturing activities required to obtain regulatory approval for OC-3 in the Territory, and the Agreement also includes a drug supply manufacturing arrangement between the parties. 1cBio will retain the right to access and use data generated under the Agreement for the purpose of its planned filing of an Investigational New Drug ("**IND**") application with the U.S. Food and Drug Administration ("**FDA**").

* *For identification purpose only*

The Group believes that the Agreement will further expand and diversify its oncology pipeline in the Territory by in-licensing a differentiated, potentially best-in-class PARP1 inhibitor, complementing the Group's existing infrastructure in drug development, clinical development, regulatory affairs, manufacturing, sales and marketing in Mainland China and the Territory.

ABOUT OC-3

OC-3 is a next-generation, PARP1-selective inhibitor currently in preclinical development. It is a potential best-in-class PARP1 inhibitor for the treatment of cancers that are defective in DNA homologous recombination repair, including prostate, ovarian, breast and pancreatic cancers with known mutations in DNA repair genes such as BRCA1, BRCA2 or PALB2. In preclinical models of cancers with this type of DNA repair deficiency, OC-3 has demonstrated potent anticancer activity. Preclinical data also suggest OC-3 has moderate PARP1 trapping activity and is designed to maintain efficacy while potentially reducing the hematologic toxicities associated with non-selective PARP inhibitors, with OC-3 expected to demonstrate PARP2 sparing at therapeutic exposures.

ABOUT 1cBio

1cBio is an emerging biotechnology company based in the San Francisco Bay Area, focused on discovering and developing innovative therapies for serious and underserved diseases, with an emphasis on oncology, metabolic disorders and conditions with limited or inadequate treatment options. 1cBio's management team brings decades of pharmaceutical industry experience with a proven track record of identifying high-potential targets and rapidly advancing small-molecule programs from discovery to clinical development. 1cBio's initial program is a potential first oral therapy for hypophosphatasia (HPP), currently in an ongoing Phase 1/2a clinical trial conducted by a development partner, and its second program, OC-3, is a potential best-in-class, selective PARP1 inhibitor initially being developed for solid tumours. More information is available at www.1cbio.com.

ABOUT LEE'S PHARM

The Company is a research-driven and market-oriented biopharmaceutical company with more than 30 years' experience in the pharmaceutical industry in China. The Company is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing based in Mainland China with global perspectives. The Company has established extensive partnerships with numerous international companies in the U.S., Europe, and Asia, and currently markets over 25 proprietary, generic and licensed-in pharmaceutical products in Mainland China, Hong Kong, Macau and Taiwan. The Company focuses on several key therapeutic areas such as cardiovascular health, women's health, paediatrics, rare diseases, oncology, dermatology and obstetrics. In addition, the Company has recently acquired U.S.-based assets in line with its strategy to broaden its portfolio of innovative drug delivery technologies, covering a wide range of indications, and reinforcing the Company's global expansion strategy. More information is available at www.leespharm.com.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board of
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 9 September 2026

As at the date of this announcement, Ms. Lee Siu Fong (Chairman) and Ms. Leelalertsuphakun Wanee are executive Directors; Dr. Li Xiaoyi, Mr. James Charles Gale and Mr. Huang Zuie-Chin are non-executive Directors; Dr. Chan Yau Ching, Bob, Ms. Cheang Yee Wah, Eva and Dr. Tsim Wah Keung, Karl, are independent non-executive Directors.